Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Rifabutin has good chemical stability and low drug resistance rate in acidic gastric environment. Therefore, it is often used in combination with amoxicillin proton pump inhibitor for the rescue treatment of Helicobacter pylori. The purpose of this study was to evaluate the efficacy and safety of rifabutin-containing triple therapy versus classical bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory Helicobacter pylori

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Amoxicillin; Bismuth; Esomeprazole; Metronidazole; Potassium Citrate; Rifabutin; Tetracycline

Criteria

Inclusion Criteria:

• ability and willingness to participate in the study and to sign and give informed consent

• Confirmed H. pylori infection and with previous treatment experience

Exclusion Criteria:

• Less than 18 years old

• With previous gastric surgery

• Previous history of tuberculosis

• Major systemic diseases

• Pregnancy or lactation

• Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion